PH29911A - Protein c derivatives - Google Patents

Protein c derivatives

Info

Publication number
PH29911A
PH29911A PH46212A PH46212A PH29911A PH 29911 A PH29911 A PH 29911A PH 46212 A PH46212 A PH 46212A PH 46212 A PH46212 A PH 46212A PH 29911 A PH29911 A PH 29911A
Authority
PH
Philippines
Prior art keywords
derivatives
human protein
protein
producing
high activity
Prior art date
Application number
PH46212A
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Brian William Grinnel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH29911A publication Critical patent/PH29911A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PH46212A 1992-05-21 1993-05-20 Protein c derivatives PH29911A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (1)

Publication Number Publication Date
PH29911A true PH29911A (en) 1996-09-16

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
PH46212A PH29911A (en) 1992-05-21 1993-05-20 Protein c derivatives

Country Status (23)

Country Link
US (1) US5453373A (ja)
EP (1) EP0575054B1 (ja)
JP (1) JP3564150B2 (ja)
KR (1) KR100291529B1 (ja)
CN (1) CN1080658A (ja)
AT (1) ATE286121T1 (ja)
AU (1) AU661901B2 (ja)
BR (1) BR9301944A (ja)
CA (1) CA2096604C (ja)
CZ (1) CZ286016B6 (ja)
DE (1) DE69333727T2 (ja)
DK (1) DK0575054T3 (ja)
ES (1) ES2233925T3 (ja)
FI (1) FI932282A (ja)
HU (1) HU218408B (ja)
IL (1) IL105757A0 (ja)
MX (1) MX9302917A (ja)
MY (1) MY110664A (ja)
NO (1) NO311299B1 (ja)
NZ (1) NZ247651A (ja)
PH (1) PH29911A (ja)
PT (1) PT575054E (ja)
RU (1) RU2122004C1 (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
WO1998048822A1 (en) 1997-04-28 1998-11-05 Eli Lilly And Company Improved methods for processing activated protein c
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CN1265598A (zh) * 1997-06-05 2000-09-06 伊莱利利公司 治疗血栓形成性疾病的方法
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO2000006179A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company Cryogranulation of activated protein c
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
DE69930419T2 (de) 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
JP2002530353A (ja) 1998-11-20 2002-09-17 イーライ・リリー・アンド・カンパニー ウイルス性出血熱の処置法
DK1133314T3 (da) 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
AU1751801A (en) * 1999-11-19 2001-05-30 Eli Lilly And Company Protein c derivatives
ES2234807T3 (es) * 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
IL154999A0 (en) * 2000-10-18 2003-10-31 Maxygen Aps Protein c or activated protein c-like molecules
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
CA2475738A1 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
EP2178556B1 (en) * 2007-06-18 2011-08-17 Oregon Health & Science University Protein c for use in maintaining hemostasis
CA2712057A1 (en) * 2008-01-15 2009-07-23 The University Of British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
KR20110114587A (ko) 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
NO311299B1 (no) 2001-11-12
KR100291529B1 (ko) 2001-06-01
PT575054E (pt) 2005-03-31
CN1080658A (zh) 1994-01-12
HU9301461D0 (en) 1993-09-28
CA2096604C (en) 2003-12-16
IL105757A0 (en) 1993-09-22
CA2096604A1 (en) 1993-11-22
FI932282A0 (fi) 1993-05-19
MY110664A (en) 1999-01-30
FI932282A (fi) 1993-11-22
AU661901B2 (en) 1995-08-10
NO931840D0 (no) 1993-05-19
CZ94893A3 (en) 1994-01-19
MX9302917A (es) 1993-11-01
US5453373A (en) 1995-09-26
HU218408B (hu) 2000-08-28
JP3564150B2 (ja) 2004-09-08
JPH0680698A (ja) 1994-03-22
AU3869993A (en) 1993-11-25
KR930023370A (ko) 1993-12-18
ATE286121T1 (de) 2005-01-15
EP0575054A2 (en) 1993-12-22
DE69333727D1 (de) 2005-02-03
EP0575054B1 (en) 2004-12-29
CZ286016B6 (cs) 1999-12-15
HUT69615A (en) 1995-09-28
NO931840L (no) 1993-11-22
EP0575054A3 (en) 1995-04-19
BR9301944A (pt) 1993-11-30
DK0575054T3 (da) 2005-04-25
ES2233925T3 (es) 2005-06-16
RU2122004C1 (ru) 1998-11-20
NZ247651A (en) 1995-03-28
DE69333727T2 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
PH29911A (en) Protein c derivatives
EP0379556A4 (en) Production of glucose oxidase in recombinant systems
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
IL110284A0 (en) Viral vectors and their use in gene therapy
GR3003991T3 (ja)
AU7130791A (en) Vectors and compounds for expression of glycosylation mutants of human protein c
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
AU5372690A (en) Genes coding for a protein having human macif activity, expression vectors containing said genes, transformant cells and proteins having human macif activity
AU6363486A (en) Promoter arrangement for streptomycetes vectors
ITRM930343A0 (it) Proteine ricombinanti, vettori per l'espressione e loro usi.